This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Bekanamycin is an aminoglycoside antibiotic indicated in the treatment of eye infections.

Generic Name
Bekanamycin
DrugBank Accession Number
DB13673
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 483.5139
Monoisotopic: 483.254042429
Chemical Formula
C18H37N5O10
Synonyms
  • Bekanamycin
External IDs
  • NK-1006

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
ArticaineThe risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Articaine.
BenzocaineThe risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Benzocaine.
Benzyl alcoholThe risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Benzyl alcohol.
BupivacaineThe risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Bupivacaine.
ButacaineThe risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Butacaine.
ButambenThe risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Butamben.
CapsaicinThe risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Capsaicin.
CefepimeThe risk or severity of ototoxicity and nephrotoxicity can be increased when Cefepime is combined with Bekanamycin.
ChloroprocaineThe risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Chloroprocaine.
CinchocaineThe risk or severity of methemoglobinemia can be increased when Bekanamycin is combined with Cinchocaine.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now

Categories

ATC Codes
J01GB13 — Bekanamycin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 4,6-disubstituted 2-deoxystreptamines. These are 2-deoxystreptamine aminoglycosides that a glycosidically linked to a pyranose of furanose unit at the C4- and C6-positions.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
4,6-disubstituted 2-deoxystreptamines
Alternative Parents
O-glycosyl compounds / Aminocyclitols and derivatives / Cyclohexylamines / Cyclohexanols / Oxanes / Monosaccharides / 1,2-aminoalcohols / Oxacyclic compounds / Acetals / Primary alcohols
show 3 more
Substituents
1,2-aminoalcohol / 4,6-disubstituted 2-deoxystreptamine / Acetal / Alcohol / Aliphatic heteromonocyclic compound / Amine / Aminocyclitol or derivatives / Cyclic alcohol / Cyclitol or derivatives / Cyclohexanol
show 15 more
Molecular Framework
Aliphatic heteromonocyclic compounds
External Descriptors
kanamycins (CHEBI:28098)
Affected organisms
Not Available

Chemical Identifiers

UNII
15JT14C3GI
CAS number
4696-76-8
InChI Key
SKKLOUVUUNMCJE-FQSMHNGLSA-N
InChI
InChI=1S/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1
IUPAC Name
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-{[(1R,2S,3S,4R,6S)-4,6-diamino-3-{[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-2-hydroxycyclohexyl]oxy}oxane-3,4-diol
SMILES
[H][C@]1(N)C[C@@]([H])(N)[C@]([H])(O[C@@]2([H])O[C@]([H])(CO)[C@@]([H])(O)[C@]([H])(N)[C@@]2([H])O)[C@@]([H])(O)[C@]1([H])O[C@@]1([H])O[C@]([H])(CN)[C@@]([H])(O)[C@]([H])(O)[C@@]1([H])N

References

General References
  1. AIFA Package Leaflet: VISUCLOBEN ANTIBIOTICO (bekanamycin and clobetasone) ophthalmic suspension [Link]
KEGG Compound
C00825
ChemSpider
388449
BindingDB
50368267
ChEBI
28098
ChEMBL
CHEMBL176
ZINC
ZINC000053132258
PDBe Ligand
9CS
Wikipedia
Bekanamycin
PDB Entries
2qir / 5u1e / 6np5 / 6nti / 6s0w / 7cl3 / 7cl5 / 7uul

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Suspension / dropsOphthalmic
Solution / dropsOphthalmic
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility75.9 mg/mLALOGPS
logP-3ALOGPS
logP-7.2Chemaxon
logS-0.8ALOGPS
pKa (Strongest Acidic)12.49Chemaxon
pKa (Strongest Basic)9.56Chemaxon
Physiological Charge5Chemaxon
Hydrogen Acceptor Count15Chemaxon
Hydrogen Donor Count11Chemaxon
Polar Surface Area288.4 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity107.79 m3·mol-1Chemaxon
Polarizability47.72 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created at June 23, 2017 20:46 / Updated at May 29, 2021 18:12